Canadian Alcohol and Drugs Survey (CADS): 2019 detailed tables

Table of contents

  1. Table 1. Alcohol indicators, by age group and sex, 2019
  2. Table 2. Alcohol indicators, by province, 2019
  3. Table 3. Alcohol impaired driving in past 12 months, within 2 hours of consuming 2 or more drinks, by sex and age group, 2019
  4. Table 4. Cannabis use in the past 12-month, past 30 days, and lifetime, by age group and sex, 2019
  5. Table 5. Cannabis use in the past 12-month, past 30 days, and lifetime, by province, 2019
  6. Table 6. Cannabis consumption methods used in the past 12 months, by sex and age group, 2019
  7. Table 7. Cannabis use status, past 3 months and past 30 days (among past 12 month cannabis users), 2019
  8. Table 8. Medical conditions reported for cannabis use (among medical and non-medical cannabis users in the past 12 months), by sex and age group, 2019
  9. Table 9. Use of cannabis in combination with other substances (among past 12 month cannabis users), by sex and age group, 2019
  10. Table 10. Cannabis products used in the past 12 months (among past 12 month cannabis users), by sex and age group, 2019
  11. Table 11. Cannabis products used in the past 12 months (among past 12 month cannabis users), by province, 2019
  12. Table 12. Driving within 2 hours of using cannabis, by sex and age group, 2019
  13. Table 13. Change in amount of cannabis used since legalization of cannabis (among past 12 month users), by sex and age group, 2019
  14. Table 14. Psychoactive pharmaceutical drug use (past 12-month), by age group and sex, 2019
  15. Table 15. Illegal drug use (past 12-month and lifetime), by age group and sex, 2019
  16. Table 16. Illegal drug use (past 12-month and lifetime), by province, 2019
  17. Table 17. Drug harms, by sex and age group, 2019
  18. Table 18. Drug overdose, by sex and age group, 2019
  19. Table 19. Drug overdose, by province, 2019
  20. Table 20. Received treatment for substance use, by sex and age group, 2019
  21. Table 21. Description of the sample, Canada, 2019
Table 1. Alcohol indicators, by age group and sex, 2019
Alcohol indicator Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,185 2,214 26,597
Alcohol
Lifetime use 87.0
[85.8-88.1]
87.8
[86.1-89.5]
86.1
[84.5-87.8]
48.5Footnote
[40.3-56.8]
89.7
[84.9-94.6]

89.8
[88.8-90.8]

Past 12 month use 76.5Footnote
[75.2-77.7]
78.3
[76.3-80.2]
74.7
[72.9-76.5]
46.3
[38.0-54.5]
84.4
[78.7-90.1]
78.2
[76.9-79.5]
Past 30 day use 61.9
[60.5-63.4]
65.6
[63.4-67.8]
58.4
[56.3-60.4]
28.6
[21.3-35.9]
68.8
[61.4-76.2]
64.0
[62.6-65.4]
Mean age of initiation (years) 17.1
[17.0-17.2]
16.8
[16.7-17.0]
17.4
[17.2-17.6]
15.2
[14.9-15.5]
16.6
[16.2-16.9]
17.3
[17.1-17.4]
Exceeding low-risk drinking guidelines (LRDG)Footnote 1
Exceeds LRDG chronic 17.6
[16.4-18.7]
18.9
[17.0-20.7]
16.3
[14.8-17.7]
10.7
[5.6-15.8]
26.2
[19.7-32.7]
17.4
[16.2-18.5]
Exceeds LRDG acute 13.1
[12.0-14.1]
14.9
[13.1-16.6]
11.4
[10.1-12.6]
6.0Footnote ^
[2.0-10.0]
21.8
[15.8-27.8]
12.9
[11.9-14.0]
Exceeds LRDG chronic - among drinkers 23.0
[21.5-24.5]
24.2
[21.9-26.5]
21.8
[19.9-23.7]
23.2Footnote *
[13.0-33.4]
31.0
[23.5-38.6]
22.2
[20.8-23.7]
Exceeds LRDG acute - among drinkers 17.2
[15.8-18.5]
19.1
[16.9-21.2]
15.2
[13.6-16.9]
12.9Footnote *,Footnote ^
[4.9-21.0]
25.8
[18.8-32.8]
16.6
[15.2-17.9]
Problems with alcohol
Any alcohol problem to selfFootnote 2 20.5Footnote
[19.1-22.0]
21.0
[18.9-23.2]
20.0
[18.1-21.9]
38.4Footnote *
[26.9-49.8]
39.6
[31.8-47.5]
17.9
[16.6-19.3]

[95% confidence intervals in brackets]

Footnote Note 1

Based on alcohol consumption in the previous 7 days.

Return to footnote 1 referrer

Footnote Note 2

At least one of 5 problems: not able to stop drinking once started, fail to do what was normally expected from you because of drinking, need a first drink in the morning to get yourself going after a heavy drinking session, been unable to remember what happened the night before because your own drinking, or have a feeling of guilt or remorse after drinking. Respondents could report multiple problems.

Return to footnote 2 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to footnote * referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to footnote ^ referrer

Footnote Note ↑

Rounds up to whole number.

Return to footnote referrer

Footnote Note ↓

Rounds down to whole number.

Return to footnote referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 2. Alcohol indicators, by province, 2019
Alcohol indicator Canada NL PE NS NB QC ON MB SK AB BC
Population estimate ('000) 30,995 440 130 813 635 7,089 12,253 1,044 893 3,558 4,140
Alcohol
Lifetime use 87.0
[85.8-88.1]
92.3
[89.8-94.9]
89.4
[86.7-92.1]
91.9
[89.6-94.1]
92.6
[90.3-94.9]
89.6
[87.6-91.7]
84.0
[81.6-86.3]
87.9
[85.2-90.5]
90.1
[87.5-92.8]
86.5Footnote
[83.6-89.3]
88.3
[85.7-91.0]
Past 12 month use 76.5Footnote
[75.2-77.7]
79.6
[76.2-83.1]
74.9
[71.2-78.6]
76.9
[73.6-80.2]
77.3
[73.8-80.8]
80.7
[78.2-83.1]
73.6
[71.0-76.2]
75.5Footnote
[72.3-78.8]
76.4
[73.0-79.7]
76.6
[73.4-79.8]
77.2
[74.0-80.4]
Past 30 day use 61.9
[60.5-63.4]
62.9
[58.9-66.9]
57.3
[52.9-61.7]
63.5Footnote
[59.7-67.2]
59.8
[55.9-63.7]
69.8
[66.9-72.6]
58.2
[55.5-61.0]
60.3
[56.7-63.8]
60.3
[56.7-63.8]
60.2
[56.6-63.7]
61.7
[58.1-65.4]
Exceeding low-risk drinking guidelines (LRDG)Footnote 1
Exceeds LRDG chronic 17.6
[16.4-18.7]
20.8
[17.2-24.4]
13.9
[10.8-17.1]
20.8
[17.3-24.3]
19.5Footnote
[16.0-22.9]
19.6
[17.1-22.0]
16.4
[14.3-18.6]
13.9
[11.4-16.5]
17.7
[14.6-20.8]
17.7
[14.8-20.6]
17.1
[14.1-20.0]
Exceeds LRDG acute 13.1
[12.0-14.1]
16.2
[12.8-19.6]
11.5Footnote
[8.5-14.5]
15.6
[12.3-18.8]
15.7
[12.4-19.0]
13.9
[11.7-16.0]
13.0
[11.0-15.1]
10.0
[7.9-12.2]
13.1
[10.3-15.8]
11.8
[9.4-14.2]
12.6
[10.1-15.1]
Exceeds LRDG chronic - among drinkers 23.0
[21.5-24.5]
26.2
[21.8-30.5]
18.6
[14.6-22.7]
27.1
[22.6-31.6]
25.2
[21.0-29.5]
24.3
[21.3-27.3]
22.3
[19.5-25.2]
18.5Footnote
[15.1-21.8]
23.2
[19.3-27.2]
23.1
[19.4-26.8]
22.1
[18.4-25.9]
Exceeds LRDG acute - among drinkers 17.2
[15.8-18.5]
20.4
[16.3-24.5]
15.3
[11.5-19.2]
20.3
[16.1-24.4]
20.3
[16.2-24.4]
17.2
[14.6-19.8]
17.8
[15.0-20.5]
13.3
[10.4-16.1]
17.1
[13.5-20.7]
15.5Footnote
[12.4-18.5]
16.4
[13.2-19.6]

[95% confidence intervals in brackets]

Footnote Note 1

Based on alcohol consumption in the previous 7 days.

Return to 1 referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 3. Alcohol impaired driving in past 12 months, within 2 hours of consuming 2 or more drinks, by sex and age group, 2019
N/A Overall Males Females 15-19 20-24 25+
Been a passenger in a vehicle driven by someone who had been drinking
Among past 12 month drinkers 8.2
[7.2-9.2]
7.6
[6.1-9.1]
8.8
[7.5-10.2]
7.0Footnote *,Footnote ^
[0.0-14.2]
14.3
[8.2-20.3]
7.7
[6.8-8.6]
Among past 12 month non-drinkers 2.0Footnote ^
[0.9-3.1]
2.0Footnote ^
[0.4-3.6]
2.0Footnote ^
[0.5-3.5]
Footnote Footnote 1.5Footnote
,Footnote ^
[0.5-2.4]
Drove a vehicle after drinking
Among past 12 month drinkers 6.4
[5.5-7.3]
9.0
[7.5-10.5]
3.5Footnote
[2.6-4.5]
Footnote 2.6Footnote ^
[0.5-4.6]
6.8
[5.8-7.8]

[95% confidence intervals in brackets]

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 4. Cannabis use in the past 12-month, past 30 days, and lifetime, by age group and sex, 2019
N/A Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,132 2,267 26,597
Cannabis use
Lifetime 41.7
[40.3-43.1]
44.4
[42.2-45.6]
39.2
[37.3-41.1]
22.8
[16.0-29.6]
54.8
[47.0-62.6]
42.1
[40.8-43.5]
Past 12 months 20.7
[19.4-22.0]
22.8
[20.9-24.8]
18.6
[16.9-20.3]
21.9
[15.2-28.7]
44.6
[36.8-52.3]
18.5Footnote
[17.3-19.8]
For medical reasons only, past 12 monthsFootnote 1 11.0
[9.2-12.8]
8.1
[5.9-10.3]
14.4
[11.6-17.2]
Footnote Footnote 13.7
[11.5-15.8]
For non-medical reasons only, past 12 monthsFootnote 1 64.0
[60.8-67.1]
68.5Footnote
[63.9-73.1]
58.5Footnote
[54.0-63.1]
Footnote # 72.1Footnote *
[62.7-81.4]
60.5Footnote
[57.1-64.0]
For both medical and non-medical purposes, past 12 monthsFootnote 1 25.1
[22.0-28.1]
23.4
[19.0-27.8]
27.0
[22.8-31.3]
Footnote # 25.4Footnote *
[16.4-34.4]
25.8
[22.4-29.2]
Past 3 months 17.0
[15.8-18.2]
19.3
[17.5-21.2]
14.7
[13.1-16.2]
19.5Footnote
[12.9-26.2]
38.6
[31.0-46.2]
14.9
[13.8-16.1]
Past 30 days 13.9
[12.8-15.0]
16.1
[14.4-17.8]
11.8
[10.4-13.1]
13.9
[8.4-19.5]
30.0
[23.0-37.0]
12.5Footnote
[11.5-13.6]
Median age of initiation to cannabis use (years) 17.0
[16.7-17.1]
17.0
[16.6-17.2]
17.0
[16.7-17.2]
Footnote # 17.0
[16.1-17.4]
17.0
[16.8-17.3]
Mean age of initiation to cannabis use (years) 19.3
[19.0-19.5]
19.0
[18.6-19.4]
19.5Footnote
[19.1-20.0]
Footnote # 17.0
[16.5-17.5]
19.7
[19.4-20.0]

[95% confidence intervals in brackets]

Footnote Note 1

Based on respondents who used cannabis in the past 12 months and responded to the question "Was it for medical reasons, non-medical reasons, or both?"

Return to 1 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 5. Cannabis use in the past 12-month, past 30 days, and lifetime, by province, 2019
N/A Canada NL PE NS NB QC ON MB SK AB BC
Population estimate ('000) 30,995 440 130 813 635 7,089 12,253 1,044 893 3,558 4,140
Cannabis use
Lifetime 41.7
[40.3-43.1]
46.9
[42.9-51.0]
44.2
[40.0-48.4]
55.2
[51.4-59.1]
49.8
[45.8-53.7]
41.5Footnote
[38.6-44.4]
39.0
[36.3-41.7]
42.8
[39.1-46.6]
41.6
[37.8-45.3]
44.9
[41.4-48.5]
42.7
[39.1-46.4]
Past 12 months 20.7
[19.4-22.0]
24.5Footnote
[20.8-28.2]
22.9
[19.5-26.3]
33.1
[29.4-36.9]
24.3
[20.5-28.0]
17.6
[14.9-20.2]
19.9
[17.5-22.3]
20.2
[17.1-23.4]
21.7
[18.4-24.9]
22.6
[19.6-25.7]
23.2
[19.8-26.6]
Past 30 days 13.9
[12.8-15.0]
15.7
[12.3-19.0]
15.9
Table [12.8-19.0]
22.6
[19.0-26.3]
18.6
[15.3-21.9]
11.4
[9.2-13.5]
13.2
[11.2-15.3]
13.5Footnote
[11.0-16.1]
14.8
[11.8-17.8]
15.9
[13.1-18.7]
15.7
[12.8-18.7]

[95% confidence intervals in brackets]

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 6. Cannabis consumption methods used in the past 12 months, by sex and age group, 2019
Cannabis consumption methodsFootnote 1 Overall Males Females 15-19 20-24 25+
Smoked 84.4
[82.0-86.8]
87.1
[83.8-90.4]
81.2
[77.8-84.6]
Footnote # 92.8Footnote *
[86.2-99.4]
81.6
[79.0-84.3]
Eaten 43.2
[39.7-46.7]
41.0
[36.1-46.0]
45.8
[40.8-50.8]
Footnote # 47.6Footnote *
[36.3-58.9]
40.8
[37.2-44.4]
Drank 4.7
[3.4-6.1]
3.9
[2.3-5.4]
5.7
[3.4-8.0]
Footnote # 4.6Footnote *,Footnote ^
[0.9-8.3]
4.5Footnote
[3.1-5.8]
Vaporized with a vaporizer 13.8
[11.3-16.2]
15.4
[11.9-18.9]
11.8
[8.4-15.2]
Footnote # 16.7Footnote *
[8.1-25.2]
13.2
[10.9-15.5]
Vaporized with a vape pen or e-cigarette 21.6
[18.5-24.6]
22.2
[17.7-26.6]
20.9
[16.7-25.1]
Footnote # 27.9Footnote *
[17.6-38.2]
19.3
[16.2-22.3]
Dabbed 6.0
[4.3-7.7]
7.9
[5.2-10.6]
3.7Footnote ^
[1.8-5.6]
Footnote # 8.9Footnote *,Footnote ^
[3.4-14.4]
4.0
[2.7-5.3]
Other 8.6
[6.8-10.4]
6.0
[3.9-8.1]
11.7
[8.7-14.7]
Footnote 4.8Footnote *,Footnote ^
[0.1-9.4]
10.0
[7.9-12.2]

[95% confidence intervals in brackets]

Footnote Note 1

Multiple methods could be reported by cannabis users.

Return to footnote 1 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 7. Cannabis use status, past 3 months and past 30 days (among past 12 month cannabis users), 2019
N/A Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,185 2,214 26,597
Cannabis use
Past 3 month cannabis use - among cannabis users in the past 12 months 84.2
[81.7-86.6]
87.1
[83.8-90.3]
80.7
[76.9-84.5]
Footnote # 88.0Footnote *
[80.5-95.5]
82.5Footnote
[79.9-85.2]
Past 30 day cannabis use - among cannabis users in the past 12 months 69.0
[65.8-72.2]
72.5Footnote
[67.9-77.2]
64.7
[60.0-69.5]
Footnote # 68.5Footnote ,Footnote *
[57.9-79.0]
69.3
[66.1-72.4]
Frequency of cannabis use in the past 3 monthsFootnote 1
Once or twice 38.5Footnote
[34.6-42.4]
34.8
[29.3-40.3]
43.3
[37.7-49.0]
Footnote # 42.2Footnote *
[29.5-54.8]
37.3
[33.3-41.2]
Monthly 15.0
[12.1-17.9]
16.2
[12.0-20.4]
13.3
[9.5-17.2]
Footnote # 13.5Footnote ,Footnote *,Footnote ^
[5.0-21.9]
14.0
[11.3-16.7]
Weekly 19.4
[16.3-22.4]
20.9
[16.2-25.7]
17.3
[13.5-21.2]
Footnote # 19.1Footnote *,Footnote ^
[10.0-28.2]
19.8
[16.4-23.3]
Daily or almost daily 27.1
[23.7-30.6]
28.0
[23.3-32.8]
26.0
[21.2-30.8]
Footnote # 25.3Footnote *
[15.2-35.3]
28.9
[25.3-32.5]
Frequency of cannabis use in the past 30 daysFootnote 2
1 day 40.5Footnote
[35.3-45.7]
36.2
[28.7-43.6]
46.1
[38.9-53.4]
Footnote # Footnote # 39.2
[33.8-44.6]
2 or 3 days 24.6
[20.1-29.1]
28.0
[21.0-35.0]
20.1
[15.0-25.2]
Footnote # Footnote # 25.3
[20.5-30.1]
1 or 2 days per week 20.9
[16.7-25.1]
20.8
[15.3-26.3]
21.0
[15.2-26.8]
Footnote # Footnote # 21.8
[17.3-26.2]
3 or 4 days per week 12.4
[8.6-16.2]
14.2
[8.3-20.1]
10.1
[5.6-14.5]
Footnote Footnote # 12.3
[7.9-16.7]
5 or 6 days per week/daily 1.6Footnote ^
[0.4-2.9]
0.8Footnote ^
[0.0-1.6]
2.7Footnote ^
[0.0-5.3]
Footnote - Footnote 1.4Footnote ^
[0.4-2.4]
Risk of developing health or other problems from cannabis useFootnote 3
Low risk of developing health and other problems 50.6
[47.0-54.1]
48.2
[42.9-53.5]
53.4
[48.4-58.3]
Footnote # 52.6Footnote *
[41.2-64.1]
51.4
[47.7-55.0]
Moderate risk of developing health and other problems 48.3
[44.8-51.8]
49.8
[44.6-55.1]
46.5Footnote
[41.5-51.4]
Footnote # 45.5Footnote ,Footnote *
[34.0-57.0]
47.5Footnote
[44.0-51.1]
High risk of developing health, other problems, cannabis dependency 1.1Footnote ^
[0.3-2.0]
2.0Footnote ^
[0.5-3.5]
Footnote Footnote - Footnote 1.1Footnote ^
[0.2-2.0]

[95% confidence intervals in brackets]

Footnote Note 1

Among respondents who used cannabis in the past 3 months.

Return to footnote 1 referrer

Footnote Note 2

Among respondents who used cannabis in the past 30 days.

Return to footnote 2 referrer

Footnote Note 3

Among respondents who used cannabis in the past 12 months, based on the WHO ASSIST screening test: https://www.who.int/substance_abuse/activities/assist_test/en/

Return to footnote 3 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 8. Medical conditions reported for cannabis use (among medical and non-medical cannabis users in the past 12 months), by sex and age group, 2019
Medical conditionsFootnote 1 Overall Males Females 15-19 20-24 25+
Arthritis 21.1
[16.0-26.3]
21.7
[12.4-30.9]
20.7
[15.1-26.2]
Footnote - Footnote 23.9
[18.2-29.6]
Depression 7.9
[3.9-11.9]
9.5Footnote
[3.1-15.9]
6.5Footnote ,Footnote ^
[1.5-11.6]
Footnote Footnote # 5.6
[2.3-9.0]
Multiple sclerosis 1.5Footnote ,Footnote ^
[0.4-2.7]
Footnote # 2.3Footnote ^
[0.3-4.2]
Footnote - Footnote - 1.8Footnote ^
[0.4-3.2]
Spinal cord injury 1.8Footnote ^
[0.6-3.1]
2.1Footnote ^
[0.0-4.3]
1.6Footnote ^
[0.3-3.0]
Footnote - Footnote - 2.2Footnote ^
[0.7-3.7]
Anxiety 32.5Footnote
[26.8-38.3]
26.3
[17.3-35.4]
37.8
[30.6-45.1]
Footnote Footnote # 28.7
[23.1-34.2]
Post-traumatic stress disorder (PTSD) 1.4Footnote ^
[0.7-2.1]
1.3Footnote ^
[0.2-2.3]
1.5Footnote ,Footnote ^
[0.4-2.6]
Footnote - Footnote 1.6Footnote ^
[0.8-2.5]
Irritable bowel syndrome or inflammatory bowel disease 2.1Footnote ^
[0.5-3.7]
3.1Footnote ^
[0.0-6.3]
1.3Footnote ^
[0.1-2.5]
Footnote - Footnote - 2.5Footnote ,Footnote ^
[0.6-4.4]
Other
31.6
[25.9-37.2]
35.5Footnote [25.9-45.0]
28.3
[21.6-34.9]
Footnote Footnote # 33.7
[27.9-39.5]

[95% confidence intervals in brackets]

Footnote Note 1

Based on respondents who reported using cannabis in the past 12 months who have used cannabis either only for medical purposes or for medical and non-medical purposes and who responded to the question "During the past 12 months, for what main medical condition did you use cannabis?"

Return to footnote 1 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 9. Use of cannabis in combination with other substances (among past 12 month cannabis users), by sex and age group, 2019
N/A Overall Males Females 15-19 20-24 25+
Alcohol 67.7
[64.4-71.0]
72.1
[67.6-76.5]
62.5Footnote
[57.8-67.2]
Footnote # 68.4Footnote *
[57.6-79.2]
67.8
[64.6-70.9]
Tobacco or e-cigarette or vaping devices 30.1
[26.6-33.6]
32.2
[27.0-37.4]
27.6
[23.2-32.1]
Footnote # 31.7Footnote *
[20.7-42.7]
28.4
[24.9-31.8]
Prescription pain relievers (e.g., oxy, Dilaudid®, morphine, Demerol®, Tylenol #3®, etc.) 2.4
[1.5-3.2]
2.5Footnote
[1.3-3.8]
2.2Footnote ^
[0.9-3.4]
Footnote Footnote 2.7
[1.7-3.8]
Prescription stimulants (e.g., Ritalin®, Concerta®, Adderall®, Dexedrine®) 2.6
[1.3-3.9]
3.3Footnote ^
[1.1-5.5]
1.8Footnote ^
[0.6-3.0]
Footnote Footnote 2.9
[1.3-4.6]
Prescription sedatives or anti-anxiety medications (e.g., diazepam, lorazepam, Valium®, Ativan®, alprazolam, Xanax®, clonazepam, Rivotril®) 7.2
[5.4-8.9]
4.8
[2.5-7.0]
10.0
[7.1-12.8]
Footnote 6.8Footnote *,Footnote ^
[1.8-11.9]
7.7
[5.7-9.8]
Illegal opioids (e.g., heroin, non-pharmaceutical fentanyl) Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Illegal stimulants (e.g., cocaine, crack, methamphetamine, ecstasy/MDMA) 4.5Footnote
[2.7-6.3]
5.2
[2.4-7.9]
3.8Footnote ^
[1.7-5.9]
Footnote 6.6Footnote *,Footnote ^
[0.7-12.4]
4.4
[2.5-6.4]
Illegal hallucinogens/dissociatives (e.g., LSD, ketamine, magic mushrooms, PCP) 5.7
[3.8-7.7]
6.5Footnote
[3.6-9.5]
4.8Footnote ^
[2.3-7.3]
Footnote # 9.3Footnote *,Footnote ^
[2.3-16.4]
4.6
[2.8-6.4]
Any combination of cannabis with other substancesFootnote 1 - among respondents who have used cannabis in the past 12 month 75.4
[72.3-78.5]
79.7
[75.8-83.5]
70.3
[65.7-74.9]
Footnote # 74.1Footnote *
[63.8-84.4]
75.3
[72.4-78.2]

[95% confidence intervals in brackets]

Footnote Note 1

Includes use of cannabis in combination with at least one of the following substances: alcohol; tobacco, e-cigarette or vaping devices; prescription pain relievers; prescription stimulants; prescription sedatives or anti-anxiety medications; illegal stimulants; illegal hallucinogens/dissociatives - respondents could report multiple combinations.

Return to footnote 1 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 10. Cannabis products used in the past 12 months (among past 12 month cannabis users), by sex and age group, 2019
Cannabis productsFootnote 1 Overall Males Females 15-19 20-24 25+
Marijuana or herb 87.7
[85.6-89.8]
90.6
[87.8-93.4]
84.3
[81.2-87.3]
Footnote # 96.8Footnote *
[92.5-100.0]
85.0
[82.6-87.5]
Hashish or kief 17.0
[14.1-19.8]
21.4
[17.0-25.8]
11.7
[8.4-14.9]
Footnote # 17.5Footnote ,Footnote *,Footnote ^
[8.9-26.2]
17.0
[14.1-19.9]
Cannabis oil 29.9
[26.7-33.0]
26.6
[22.4-30.8]
33.8
[29.2-38.5]
Footnote # 31.3Footnote *
[20.9-41.7]
30.2
[27.0-33.4]
Cannabis cartridges or disposable vape pens 15.6
[13.0-18.2]
16.9
[13.1-20.8]
14.0
[10.6-17.3]
Footnote # 17.5Footnote ,Footnote *
[9.8-25.2]
14.3
[11.7-16.9]
Liquid concentrate
(e.g., butane honey oil)
6.5Footnote
[4.6-8.3]
7.1
[4.7-9.5]
5.7
[3.0-8.4]
Footnote # 6.1Footnote *,Footnote ^
[2.1-10.1]
5.6
[3.8-7.4]
Solid concentrate 8.9
[7.0-10.9]
9.7
[7.0-12.4]
8.0
[5.1-11.0]
Footnote # 12.0Footnote *,Footnote ^
[5.6-18.4]
7.7
[5.8-9.7]
Edibles 42.3
[38.8-45.8]
40.4
[35.5-45.4]
44.5Footnote
[39.4-49.5]
Footnote # 49.3Footnote *
[38.4-60.1]
39.4
[35.7-43.0]
Liquid
(e.g., cola, tea, coffee)
2.3
[1.4-3.3]
2.3
[1.2-3.4]
2.4Footnote ^
[0.9-3.8]
Footnote # 1.6Footnote *,Footnote ^
[0.0-3.4]
2.6
[1.5-3.7]
Other 1.2
[0.6-1.8]
0.8Footnote ^
[0.1-1.5]
1.6Footnote ^
[0.6-2.6]
Footnote - Footnote # 1.4Footnote ^
[0.6-2.2]

[95% confidence intervals in brackets]

Footnote Note 1

Based on cannabis users in the past 12 months who responded to the question"During the past 12 months, which of the following cannabis products have you used?" - respondents could report multiple cannabis products.

Return to footnote 1 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 11. Cannabis products used in the past 12 months (among past 12 month cannabis users), by province, 2019
Cannabis productsFootnote 1 Canada NL PE NS NB QC ON MB SK AB BC
Marijuana or herb 87.7
[85.6-89.8]
87.6Footnote *
[82.3-92.8]
93.1Footnote *
[89.6-96.5]
87.4
[83.3-91.6]
82.1
[76.0-88.3]
91.1
[87.3-94.9]
87.7
[83.7-91.6]
90.6
[86.3-95.0]
85.5Footnote ,Footnote *
[79.6-91.4]
85.0
[79.6-90.4]
86.2
[80.4-91.9]
Hashish or kief 17.0
[14.1-19.8]
21.4Footnote *,Footnote ^
[11.6-31.2]
18.7Footnote *,Footnote ^
[9.2-28.2]
15.3
[9.3-21.2]
19.1
[11.3-26.8]
20.0
[13.1-26.8]
17.5Footnote
[12.0-23.0]
12.6Footnote ^
[6.5-18.6]
18.7Footnote *,Footnote ^
[11.0-26.4]
11.9Footnote ^
[6.8-17.0]
16.1Footnote ^
[9.0-23.1]
Cannabis oil 29.9
[26.7-33.0]
39.5Footnote ,Footnote *
[29.5-49.5]
32.8Footnote *
[22.9-42.7]
37.3
[28.9-45.7]
44.9
[35.6-54.3]
15.2
[9.6-20.8]
29.2
[23.1-35.3]
29.5Footnote
[21.6-37.4]
37.9Footnote *
[29.1-46.7]
35.8
[28.5-43.1]
38.8
[30.1-47.5]
Cannabis cartridges or disposable vape pens 15.6
[13.0-18.2]
12.5Footnote ,Footnote *,Footnote ^
[4.5-20.5]
9.9Footnote *,Footnote ^
[3.7-16.1]
13.2Footnote ^
[7.2-19.2]
15.1Footnote ^
[7.6-22.6]
6.1Footnote ^
[2.9-9.3]
15.5Footnote
[10.2-20.9]
21.5Footnote
[14.4-28.7]
23.2Footnote *
[15.5-30.8]
16.5Footnote ,Footnote ^
[10.2-22.9]
25.8
[17.6-33.9]
Liquid concentrate (e.g., butane honey oil) 6.5Footnote
[4.6-8.3]
8.7Footnote *,Footnote ^
[1.7-15.7]
5.6Footnote *,Footnote ^
[1.3-9.9]
9.4Footnote ^
[4.3-14.6]
10.5Footnote ,Footnote ^
[3.3-17.6]
3.5Footnote ,Footnote ^
[1.0-5.9]
5.3Footnote ^
[1.7-8.9]
12.1Footnote ^
[6.3-18.0]
9.4Footnote *,Footnote ^
[3.7-15.2]
9.0Footnote ^
[4.0-14.0]
7.7Footnote ^
[2.3-13.1]
Solid concentrate 8.9
[7.0-10.9]
11.4Footnote *,Footnote ^
[3.4-19.3]
12.1Footnote *,Footnote ^
[4.8-19.4]
8.9Footnote ^
[4.1-13.7]
15.8Footnote ^
[7.9-23.6]
1.7Footnote ^
[0.0-3.4]
6.8Footnote ^
[3.0-10.6]
12.8Footnote ^
[6.9-18.7]
12.0Footnote *,Footnote ^
[5.6-18.4]
13.3Footnote ^
[7.7-18.9]
17.4Footnote ^
[10.2-24.7]
Edibles 42.3
[38.8-45.8]
40.0Footnote *
[29.9-50.2]
35.8Footnote *
[25.5-46.0]
34.8
[26.8-42.9]
39.0
[29.5-48.4]
17.4
[11.4-23.4]
53.0
[46.2-59.8]
46.3
[37.6-55.0]
42.5Footnote ,Footnote *
[33.6-51.5]
44.8
[36.9-52.6]
47.6
[38.6-56.5]
Liquid (e.g., cola, tea, coffee) 2.3
[1.4-3.3]
5.0Footnote *,Footnote ^
[0.2-9.8]
3.4Footnote *,Footnote ^
[0.0-6.9]
2.2Footnote ^
[0.4-4.1]
4.0Footnote ^
[0.9-7.2]
Footnote 2.0Footnote ^
[0.5-3.6]
5.8Footnote ^
[1.5-10.1]
5.0Footnote *,Footnote ^
[0.2-9.8]
Footnote 5.8Footnote ^
[1.7-9.9]
Other 1.2
[0.6-1.8]
Footnote 2.0Footnote *,Footnote ^
[0.0-4.2]
3.4Footnote ^
[0.6-6.2]
Footnote Footnote 1.1Footnote ^
[0.1-2.2]
Footnote Footnote Footnote Footnote

[95% confidence intervals in brackets]

Footnote Note 1

Based on cannabis users in the past 12 months who responded to the question"During the past 12 months, which of the following cannabis products have you used?" - respondents could report multiple cannabis products

Return to footnote 1 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 12. Driving within 2 hours of using cannabis, by sex and age group, 2019
Alcohol indicator Overall Males Females 15-19 20-24 25+
Passenger in a vehicle driven by someone who used cannabis in the past 2 hours
Among all respondents 4.6
[3.9-5.3]
4.7
[3.7-5.7]
4.5Footnote
[3.6-5.4]
7.0Footnote ^
[3.5-10.5]
12.7
[7.9-17.6]
3.7
[3.1-4.3]
Among past 12 month cannabis users 17.9
[15.0-20.7]
17.9
[14.0-21.8]
17.8
[13.8-21.8]
Footnote # 23.6Footnote *
[14.5-32.7]
16.0
[13.3-18.8]
Among past 12 month cannabis non-users 1.3
[0.9-1.6]
0.9
[0.5-1.4]
1.6
[1.0-2.1]
2.3Footnote ^
[0.4-4.3]
3.7Footnote *,Footnote ^
[0.1-7.2]
1.0
[0.7-1.3]
Drove a vehicle within 2 hours of using cannabis
Among past 12 month cannabis users 9.2
[7.0-11.4]
11.0
[7.9-14.0]
6.8
[3.9-9.7]
Footnote # 14.2Footnote *,Footnote ^
[5.6-22.8]
8.4
[6.3-10.6]

[95% confidence intervals in brackets]

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 13. Change in amount of cannabis used since legalization of cannabis (among past 12 month users), by sex and age group, 2019Footnote 1
N/A Overall Males Females 15-19 20-24 25+
More 30.8
[27.6-34.0]
26.5Footnote
[22.3-30.7]
35.9
[31.1-40.8]
Footnote # 28.5Footnote ,Footnote *
[18.4-38.6]
29.4
[26.2-32.5]
Less 26.4
[23.2-29.6]
28.7
[24.0-33.4]
23.6
[19.1-28.1]
Footnote # 37.1Footnote *
[25.6-48.6]
23.8
[20.6-26.9]
The same 42.8
[39.3-46.4]
44.8
[39.8-49.8]
40.5Footnote
[35.8-45.2]
Footnote # 34.3Footnote *
[23.2-45.5]
46.8
[43.1-50.5]

[95% confidence intervals in brackets]

Footnote Note 1

Based on respondents who used cannabis in the past 12 month and who provided a response to the question "During the past 12 months, have you consumed more, less or the same quantity of cannabis compared to the year before?"

Return to footnote 1 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 14. Psychoactive pharmaceutical drug use (past 12-month), by age group and sex, 2019
Pharmaceutical Drug Category Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,185 2,214 26,597
Pain RelieversFootnote 1
Pain relievers (incl. low-dose codeine) 14.2
[13.1-15.2]
12.3
[10.9-13.7]
16.0
[14.5-17.6]
9.8Footnote ^
[4.2-15.3]
12.1
[7.1-17.1]
14.7
[13.6-15.8]
Pain relievers (excl. low-dose codeine) 6.9
[6.2-7.6]
6.0
[5.1-7.0]
7.7
[6.7-8.8]
3.4Footnote ^
[0.8-6.0]
6.7Footnote ^
[2.8-10.6]
7.2
[6.4-8.0]
Problematic use of pain relievers (incl. low-dose codeine) - all respondents 0.9
[0.6-1.2]
0.8Footnote ^
[0.4-1.3]
0.9Footnote ^
[0.5-1.4]
Footnote 1.0Footnote ^
[0.0-2.4]
0.9
[0.5-1.2]
Problematic use of pain relievers (incl. low-dose codeine) - among those who have used pain relievers 6.3
[4.1-8.4]
6.9
[3.5-10.3]
5.9
[3.0-8.7]
Footnote Footnote # 6.0
[3.8-8.2]
Problematic use of pain relievers (excl. low-dose codeine) - all respondents 0.4
[0.2-0.6]
0.5Footnote ^
[0.1-0.8]
0.3Footnote ^
[0.0-0.5]
Footnote 1.0Footnote ^
[0.0-2.4]
0.3Footnote ^
[0.1-0.5]
Problematic use of pain relievers (excl. low-dose codeine) - among those who have used pain relievers 5.3
[2.3-8.2]
7.9Footnote ^
[2.2-13.7]
3.3Footnote ^
[0.5-6.0]
Footnote Footnote # 4.6Footnote ^
[1.6-7.5]
StimulantsFootnote 2
Stimulants 2.1
[1.6-2.7]
2.1
[1.3-2.9]
2.1
[1.4-2.9]
4.7Footnote ^
[1.4-8.1]
9.1Footnote ^
[4.5-13.7]
1.3
[0.9-1.8]
Problematic use of stimulants 0.8
[0.4-1.2]
1.0Footnote ^
[0.3-1.7]
0.6Footnote ^
[0.2-1.0]
0.9Footnote ^
[0.0-1.9]
4.8Footnote ^
[1.4-8.1]
0.4Footnote ^
[0.1-0.8]
Problematic use of stimulants - among those who have used stimulants 37.0Footnote *
[23.7-50.2]
Footnote # Footnote # Footnote # Footnote # 32.9Footnote *,Footnote ^
[15.3-50.5]
SedativesFootnote 3
Sedatives 10.7
[9.8-11.5]
7.3
[6.3-8.4]
13.9
[12.6-15.2]
3.4Footnote ^
[1.0-5.8]
12.0
[7.2-16.7]
11.1
[10.3-12.0]
Sedatives to get high 0.3Footnote ^
[0.0-0.5]
0.4Footnote ^
[0.0-0.8]
0.2Footnote ^
[0.0-0.3]
Footnote Footnote 0.2Footnote ^
[0.0-0.4]
Sedatives to get high - among users 2.6Footnote ^
[0.5-4.7]
5.3Footnote ^
[0.0-11.1]
1.2Footnote ^
[0.4-1.9]
Footnote Footnote 1.7Footnote ^
[0.0-3.5]
Any pharmaceuticals
Any pharmaceutical (incl. low-dose codeine pain relievers) 22.7
[21.5-23.9]
18.7
[16.9-20.4]
26.7
[24.9-28.4]
14.9
[8.7-21.0]
26.8
[20.1-33.5]
23.0
[21.8-24.3]
Any pharmaceutical (excl. low-dose codeine pain relievers) 16.9
[15.9-18.0]
13.3
[11.8-14.7]
20.5Footnote
[19.0-22.1]
10.2
[5.7-14.8]
22.5Footnote
[16.2-28.7]
17.0
[15.9-18.1]
Problematic use of any pharmaceuticals (incl. low-dose codeine pain relievers) 1.6
[1.1-2.1]
1.7
[1.0-2.4]
1.5Footnote
[0.9-2.1]
1.3Footnote ^
[0.1-2.4]
5.5Footnote ,Footnote ^
[2.1-8.9]
1.3
[0.9-1.7]
Problematic use of any pharmaceutical (excl. low-dose codeine pain relievers) 1.1
[0.7-1.5]
1.4
[0.7-2.0]
0.9
[0.5-1.3]
0.9Footnote ^
[0.0-1.9]
5.5Footnote ,Footnote ^
[2.1-8.9]
0.8
[0.4-1.1]
Problematic use of any pharmaceutical (incl. low-dose codeine pain relievers) - among users of any pharmaceutical 7.1
[5.1-9.1]
9.2
[5.5-12.9]
5.7
[3.6-7.8]
Footnote # 20.5Footnote ,Footnote *,Footnote ^
[8.9-32.1]
5.7
[3.8-7.5]
Problematic use of any pharmaceutical (excl. low-dose codeine pain relievers) - among users of any pharmaceutical 6.6
[4.3-9.0]
10.3
[5.4-15.1]
4.3
[2.3-6.4]
Footnote # Footnote # 4.5Footnote
[2.4-6.5]

[95% confidence intervals in brackets]

Footnote Note 1

Pain relievers are products that contain opioids such as codeine or morphine, or related drugs. Most of these products require a prescription, although some do not. Includes prescribed or non-prescribed drugs such as Tylenol 1, 2, 3, and 4, or 292s. Excludes Regular Tylenol or Extra Strength Tylenol, Aspirin, Advil, Motrin or their generic equivalents.

Return to footnote 1 referrer

Footnote Note 2

Stimulants refers to products that require a prescription such as Ritalin, Concerta, Adderall or Dexedrine to help people who have attention or concentration problems such as ADHD. Excludes over-the-counter medications.

Return to footnote 2 referrer

Footnote Note 3

Sedatives are products that require a prescription such as diazepam, Valium, lorazepam, Ativan, alprazolam, Xanax, clonazepam, Rivotril or others. Excludes over-the-counter medications.

Return to footnote 3 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 15. Illegal drug use (past 12-month and lifetime), by age group and sex, 2019
Drug Category Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,185 2,214 26,597
Illegal drug use past 12 months
Cocaine/Crack 2.0
[1.4-2.5]
2.4
[1.6-3.2]
1.5Footnote
[0.9-2.2]
Footnote 9.0Footnote ^
[4.6-13.3]
1.5Footnote
[1.0-1.9]
Methamphetamine/ amphetamines 0.5Footnote ,Footnote ^
[0.2-0.7]
0.8Footnote ^
[0.3-1.3]
0.1Footnote ^
[0.0-0.3]
Footnote - Footnote # 0.4Footnote ^
[0.1-0.6]
Hallucinogens 1.9
[1.4-2.4]
2.3
[1.5-3.1]
1.5Footnote
[1.0-2.0]
2.2Footnote ^
[0.0-4.5]
5.7Footnote ^
[2.1-9.3]
1.5Footnote
[1.1-2.0]
Ecstasy 1.1
[0.7-1.6]
1.3
[0.6-1.9]
1.0Footnote ^
[0.5-1.5]
Footnote 5.5Footnote ,Footnote ^
[1.8-9.3]
0.8
[0.4-1.1]
Salvia Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Heroin Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Inhalants 0.1Footnote ^
[0.0-0.2]
Footnote Footnote Footnote Footnote - Footnote
Synthetic cannabinoids 0.0Footnote ^
[0.0-0.1]
Footnote Footnote Footnote - Footnote - 0.1Footnote ^
[0.0-0.1]
Mephedrone Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
BZP/ TFMPP Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Kratom 0.2Footnote ^
[0.0-0.4]
0.3Footnote ^
[0.0-0.6]
Footnote Footnote - Footnote 0.2Footnote ^
[0.0-0.4]
Other drugs 0.3Footnote ^
[0.1-0.6]
0.6Footnote ^
[0.1-1.2]
0.1Footnote ^
[0.0-0.1]
Footnote Footnote 0.3Footnote ^
[0.0-0.5]
Any of 6 drugsFootnote 1 3.5Footnote
[2.9-4.1]
4.0
[3.0-5.0]
3.0
[2.2-3.7]
3.0Footnote ^
[0.4-5.5]
13.7
[8.5-18.9]
2.7
[2.1-3.2]
Any of 11 drugsFootnote 2 3.8
[3.2-4.5]
4.5Footnote
[3.4-5.6]
3.2
[2.4-3.9]
3.6Footnote ^
[0.8-6.5]
13.7
[8.5-18.9]
3.0
[2.4-3.6]
Any drugFootnote 3 4.6
[3.9-5.3]
5.2
[4.1-6.3]
4.1
[3.2-5.0]
4.3Footnote ^
[1.4-7.3]
14.2
[9.0-19.5]
3.8
[3.2-4.5]
Lifetime illegal drug use
Cocaine/Crack 8.5Footnote
[7.6-9.3]
10.5Footnote
[9.1-11.9]
6.5Footnote
[5.6-7.5]
1.6Footnote ^
[0.0-3.6]
15.5Footnote
[10.1-20.8]
8.4
[7.6-9.3]
Methamphetamine/ amphetamines 3.2
[2.6-3.8]
4.1
[3.1-5.1]
2.3
[1.7-2.9]
Footnote 6.7Footnote ^
[2.7-10.7]
3.0
[2.5-3.5]
Hallucinogens 11.8
[10.9-12.7]
14.1
[12.7-15.5]
9.6
[8.5-10.7]
2.5Footnote ,Footnote ^
[0.2-4.9]
15.1
[9.9-20.3]
12.3
[11.3-13.2]
Ecstasy 6.6
[5.8-7.4]
7.1
[5.9-8.3]
6.1
[5.1-7.2]
1.1Footnote ^
[0.0-2.4]
14.7
[9.1-20.4]
6.4
[5.6-7.1]
Salvia 2.2
[1.7-2.7]
3.1
[2.3-3.9]
1.3
[0.8-1.8]
Footnote 4.8Footnote ^
[1.8-7.9]
2.1
[1.6-2.6]
Heroin 0.5Footnote
[0.3-0.7]
0.7
[0.3-1.2]
0.2Footnote ^
[0.1-0.4]
Footnote Footnote 0.5Footnote
[0.3-0.8]
Inhalants 0.8
[0.6-1.1]
1.2
[0.8-1.6]
0.5Footnote ,Footnote ^
[0.2-0.7]
Footnote Footnote 0.9
[0.7-1.2]
Synthetic cannabinoids 0.5Footnote
[0.2-0.7]
0.7Footnote ^
[0.2-1.2]
0.3Footnote ^
[0.1-0.5]
Footnote - Footnote 0.5Footnote
[0.3-0.8]
Mephedrone 0.1Footnote ^
[0.0-0.2]
0.1Footnote ^
[0.0-0.3]
Footnote Footnote Footnote - 0.1Footnote ^
[0.0-0.2]
BZP/ TFMPP Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Kratom 0.5Footnote ,Footnote ^
[0.2-0.8]
0.7Footnote ^
[0.2-1.2]
0.3Footnote ^
[0.1-0.6]
Footnote - Footnote 0.5Footnote ,Footnote ^
[0.2-0.8]
Other drugs to get high 1.5Footnote
[1.1-1.9]
2.2
[1.4-2.9]
0.9
[0.5-1.2]
Footnote 3.5Footnote ,Footnote ^
[0.8-6.3]
1.4
[1.0-1.8]
Any of 6 drugsFootnote 1 16.1
[15.1-17.2]
18.3
[16.6-19.9]
14.1
[12.7-15.4]
4.1Footnote ^
[1.1-7.1]
25.2
[18.5-31.8]
16.3
[15.2-17.4]
Any of 12 drugsFootnote 4 16.9
[15.8-18.0]
19.2
[17.5-20.9]
14.6
[13.2-16.0]
5.0Footnote ^
[1.8-8.2]
25.2
[18.5-31.8]
17.1
[16.0-18.3]
Any drugFootnote 3 17.5Footnote
[16.3-18.6]
19.6
[17.9-21.3]
15.4
[13.9-16.8]
5.7Footnote ^
[2.4-9.0]
25.7
[19.1-32.4]
17.7
[16.6-18.9]

[95% confidence intervals in brackets]

Footnote Note 1

Cocaine/crack, speed/methamphetamine, ecstasy, hallucinogens, heroin, salvia.

Return to footnote 1 referrer

Footnote Note 2

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom, other drugs.

Return to footnote 2 referrer

Footnote Note 3

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom, BZP/TFMPP, other drugs to get high, problematic use of pain relievers (including low dose pain relievers), problematic use of stimulants, sedatives to get high.

Return to footnote 3 referrer

Footnote Note 4

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, BZP/ TFMPP, kratom, other drugs to get high - excluding cannabis.

Return to footnote 4 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 16. Illegal drug use (past 12-month and lifetime), by province, 2019
Alcohol indicator Canada NL PE NS NB QC ON MB SK AB BC
Population estimate ('000) 30,995 440 130 813 635 7,089 12,253 1,044 893 3,558 4,140
Illegal drug use past year
Cocaine/Crack 2.0
[1.4-2.5]
2.1Footnote ^
[0.5-3.6]
1.1Footnote ^
[0.2-2.0]
2.3Footnote ^
[0.3-4.3]
1.4Footnote ^
[0.0-3.0]
1.8Footnote ^
[0.9-2.8]
2.3Footnote ^
[1.2-3.4]
1.5Footnote ,Footnote ^
[0.5-2.5]
1.7Footnote ^
[0.6-2.8]
2.6Footnote ^
[1.3-3.9]
0.8Footnote ^
[0.1-1.5]
Amphetamines/Methamphetamine 0.5Footnote ,Footnote ^
[0.2-0.7]
Footnote - Footnote Footnote Footnote 0.7Footnote ^
[0.1-1.3]
0.5Footnote ,Footnote ^
[0.0-1.0]
Footnote Footnote Footnote Footnote
Hallucinogens 1.9
[1.4-2.4]
Footnote 0.9Footnote ^
[0.0-1.8]
0.9Footnote ^
[0.0-1.9]
Footnote 1.7Footnote ^
[0.8-2.5]
1.7Footnote ^
[0.7-2.6]
1.0Footnote ^
[0.4-1.6]
1.3Footnote ^
[0.4-2.1]
3.0Footnote ^
[1.5-4.4]
2.8Footnote ^
[1.4-4.2]
Ecstasy 1.1
[0.7-1.6]
Footnote Footnote Footnote Footnote 0.7Footnote ^
[0.1-1.3]
1.5Footnote ,Footnote ^
[0.5-2.4]
Footnote Footnote 2.1Footnote ^
[0.9-3.4]
0.7Footnote ^
[0.2-1.3]
Salvia Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Heroin Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Inhalants 0.1Footnote ^
[0.0-0.2]
Footnote - Footnote - Footnote - Footnote - Footnote - Footnote Footnote - Footnote Footnote Footnote
Synthetic cannabinoids 0.0Footnote ^
[0.0-0.1]
Footnote - Footnote Footnote Footnote Footnote - Footnote Footnote - Footnote - Footnote - Footnote
Mephedrone Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Kratom 0.2Footnote ^
[0.0-0.4]
Footnote - Footnote - Footnote Footnote Footnote - Footnote Footnote Footnote Footnote Footnote -
Other drugs 0.3Footnote ^
[0.1-0.6]
Footnote Footnote - Footnote Footnote Footnote Footnote Footnote Footnote Footnote Footnote
Any of 6 drugsFootnote 1 3.5Footnote
[2.9-4.1]
2.2Footnote ^
[0.7-3.8]
2.2Footnote ^
[0.8-3.5]
3.2Footnote ^
[1.0-5.5]
2.2Footnote ^
[0.5-4.0]
3.2
[2.0-4.4]
3.5Footnote
[2.2-4.8]
2.6Footnote ^
[1.4-3.8]
2.3Footnote ^
[1.1-3.6]
4.8
[3.1-6.6]
3.8
[2.2-5.3]
Any of 11 drugsFootnote 2 3.8
[3.2-4.5]
2.2Footnote ^
[0.7-3.8]
2.2Footnote ^
[0.8-3.5]
4.2Footnote ^
[1.8-6.6]
2.6Footnote ^
[0.8-4.5]
3.4
[2.1-4.6]
3.9
[2.5-5.3]
2.8Footnote ^
[1.5-4.0]
2.7Footnote ^
[1.3-4.1]
5.0
[3.2-6.7]
4.2
[2.5-5.8]
Any drugFootnote 3 4.6
[3.9-5.3]
2.5Footnote ,Footnote ^
[0.9-4.1]
2.4Footnote ^
[1.0-3.8]
5.2Footnote ^
[2.7-7.6]
3.6Footnote ^
[1.6-5.7]
4.2
[2.9-5.6]
4.7
[3.3-6.2]
3.4Footnote ^
[2.0-4.7]
3.4Footnote ^
[1.9-5.0]
6.1
[4.3-8.0]
4.6
[2.9-6.3]
Lifetime illegal drug use
Cocaine/Crack 8.5Footnote
[7.6-9.3]
6.3
[3.9-8.6]
6.2
[4.2-8.2]
8.4
[5.8-11.0]
7.9
[5.0-10.8]
9.2
[7.5-10.9]
8.0
[6.3-9.7]
7.6
[5.5-9.8]
8.6
[6.2-11.0]
8.7
[6.8-10.7]
9.0
[7.1-10.9]
Amphetamines/Methamphetamine 3.2
[2.6-3.8]
1.3Footnote ^
[0.3-2.3]
1.7Footnote ^
[0.7-2.7]
2.5Footnote ,Footnote ^
[1.3-3.6]
4.1Footnote ^
[1.9-6.3]
5.5Footnote
[4.0-7.0]
2.7
[1.7-3.7]
1.7Footnote ^
[0.7-2.6]
1.8Footnote ^
[0.8-2.8]
2.5Footnote ,Footnote ^
[1.4-3.6]
2.1Footnote ^
[1.3-3.0]
Hallucinogens 11.8
[10.9-12.7]
10.4
[7.8-13.1]
9.0
[6.4-11.6]
12.8
[10.1-15.5]
13.6
[10.3-16.8]
10.9
[9.0-12.7]
10.6
[8.8-12.4]
12.6
[10.2-15.0]
10.4
[8.0-12.7]
14.9
[12.4-17.5]
14.2
[11.6-16.7]
Ecstasy 6.6
[5.8-7.4]
4.0Footnote ^
[2.2-5.7]
5.1
[3.0-7.3]
7.4
[5.4-9.5]
6.1Footnote ^
[3.2-8.9]
6.8
[5.1-8.6]
6.5Footnote
[4.9-8.0]
5.8
[3.9-7.7]
4.9
[3.1-6.6]
7.2
[5.3-9.1]
7.1
[5.4-8.8]
Salvia 2.2
[1.7-2.7]
1.2Footnote ^
[0.3-2.1]
2.2Footnote ^
[0.8-3.6]
1.9Footnote ^
[0.7-3.1]
3.0Footnote ^
[1.3-4.7]
2.8Footnote ^
[1.6-3.9]
1.9Footnote ^
[1.0-2.8]
2.8Footnote ^
[1.5-4.0]
2.1Footnote ^
[1.0-3.2]
2.8Footnote ^
[1.5-4.0]
1.4Footnote ^
[0.6-2.2]
Heroin 0.5Footnote
[0.3-0.7]
Footnote - Footnote 0.8Footnote ^
[0.1-1.5]
Footnote 0.4Footnote ^
[0.0-0.7]
0.6Footnote ^
[0.1-1.1]
Footnote Footnote Footnote 0.6Footnote ^
[0.1-1.0]
Inhalants 0.8
[0.6-1.1]
Footnote 1.4Footnote ^
[0.3-2.4]
1.3Footnote ^
[0.4-2.1]
0.7Footnote ^
[0.1-1.3]
0.9Footnote ^
[0.5-1.4]
0.4Footnote ^
[0.1-0.7]
0.7Footnote ^
[0.1-1.2]
1.2Footnote ^
[0.3-2.1]
1.6Footnote ^
[0.7-2.4]
1.3Footnote ^
[0.5-2.1]
Synthetic cannabinoids 0.5Footnote
[0.2-0.7]
Footnote Footnote Footnote Footnote Footnote Footnote Footnote Footnote - 1.0Footnote ^
[0.1-1.9]
0.6Footnote ^
[0.0-1.2]
Mephedrone 0.1Footnote ^
[0.0-0.2]
Footnote Footnote Footnote Footnote Footnote - Footnote Footnote Footnote - Footnote Footnote
Kratom 0.5Footnote ,Footnote ^
[0.2-0.8]
Footnote - Footnote Footnote Footnote Footnote - 0.8Footnote ^
[0.1-1.4]
Footnote Footnote 1.2Footnote ^
[0.2-2.2]
Footnote
BZP/TFMPP Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote - Footnote -
Other drugs 1.5Footnote
[1.1-1.9]
1.6Footnote ^
[0.3-2.9]
Footnote 1.5Footnote ,Footnote ^
[0.5-2.5]
Footnote 1.7Footnote ^
[0.7-2.7]
1.5Footnote ,Footnote ^
[0.7-2.3]
0.7Footnote ^
[0.1-1.2]
0.9Footnote ^
[0.3-1.6]
1.9Footnote ^
[0.8-2.9]
1.4Footnote ^
[0.6-2.2]
Any of 6 drugsFootnote 1 16.1
[15.1-17.2]
12.7
[9.9-15.6]
12.1
[9.1-15.1]
16.9
[13.7-20.1]
19.4
[15.6-23.1]
17.8
[15.5-20.2]
14.2
[12.2-16.1]
16.5Footnote
[13.7-19.4]
13.4
[10.7-16.2]
18.0
[15.3-20.8]
17.8
[15.1-20.6]
Any of 12 drugsFootnote 4 16.9
[15.8-18.0]
13.5Footnote
[10.5-16.5]
12.8
[9.7-15.8]
17.7
[14.5-21.0]
19.8
[16.0-23.6]
18.3
[16.0-20.7]
14.8
[12.8-16.9]
17.3
[14.4-20.2]
14.4
[11.5-17.3]
19.3
[16.4-22.1]
18.7
[15.9-21.5]
Any drugFootnote 3 17.5Footnote
[16.3-18.6]
13.8
[10.8-16.8]
13.1
[10.0-16.1]
18.4
[15.1-21.7]
20.3
[16.5-24.1]
19.3
[16.9-21.6]
15.4
[13.3-17.5]
17.5Footnote
[14.7-20.4]
15.1
[12.2-18.1]
19.8
[17.0-22.7]
18.9
[16.1-21.7]
Drug related harms in past yearFootnote 5
Drug related harms in past year- all respondentsFootnote 6 4.5Footnote
[3.7-5.3]
6.4Footnote ^
[3.3-9.5]
2.9Footnote ^
[1.1-4.7]
5.8
[3.2-8.3]
4.2Footnote ^
[1.9-6.4]
4.1
[2.6-5.7]
5.0
[3.3-6.8]
3.4Footnote ^
[1.8-5.1]
4.8Footnote ^
[2.8-6.8]
5.0Footnote ^
[3.0-7.0]
3.0Footnote ^
[1.5-4.4]

[95% confidence intervals in brackets]

Footnote Note 1

Cocaine/crack, speed/methamphetamine, ecstasy, hallucinogens, heroin, salvia

Return to footnote 1 referrer

Footnote Note 2

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, heroin, inhalants, salvia, synthetic cannabinoids, mephredone, kratom, other drugs to get high.

Return to footnote 2 referrer

Footnote Note 3

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom,BZP, other drugs to get high, problematic use of pain relievers, problematic use of stimulants, sedatives to get high.

Return to footnote 3 referrer

Footnote Note 4

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, heroin, inhalants, salvia, synthetic cannabinoids, mephredone, kratom, BZP/ TFMPP, other drugs to get high.

Return to footnote 4 referrer

Footnote Note 5

At least one of 9 harms to: physical health; mental health; friendships and social life; financial position; home life or marriage; work, studies, or employment opportunities; legal problems; difficulty learning; housing problems.

Return to footnote 5 referrer

Footnote Note 6

Asked of those who used any drug (cannabis, cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom, other drugs to get high, problematic use of pain relievers, problematic use of stimulants and sedatives to get high).

Return to footnote 6 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 17. Drug harms, by sex and age group, 2019
Drug related harms in past yearFootnote 1 Overall Males Females 15-19 20-24 25+
Population estimate ('000) 30,995 15,293 15,702 2,132 2,267 26,597
Any drug harm to self - total population 4.5Footnote
[3.7-5.3]
5.2
[3.9-6.4]
3.9
[2.8-4.9]
5.9Footnote ^
[1.7-10.1]
13.8
[8.3-19.3]
3.4
[2.7-4.1]
Any drug harm to self among users of any 6 drugsFootnote 2 49.0
[39.8-58.2]
53.2Footnote *
[41.1-65.2]
43.5Footnote ,Footnote *
[29.6-57.4]
Footnote # Footnote # 41.7
[30.9-52.5]
Any drug harm to self among users of any 11 drugsFootnote 3 47.8
[38.9-56.7]
52.2Footnote *
[40.6-63.8]
41.8Footnote *
[28.4-55.2]
Footnote # Footnote # 41.7
[31.3-52.0]
Any drug harm to self among those who have engaged in problematic use of any pharmaceuticalsFootnote 4 46.8Footnote *
[31.7-61.8]
Footnote # Footnote # Footnote # Footnote # 38.7Footnote *
[20.3-57.1]
Any drug harm to self among those who have used any 11 drugs/ problematic use of pharmaceuticalsFootnote 5 16.6
[13.8-19.4]
17.4
[13.4-21.4]
15.6
[11.6-19.5]
Footnote # 27.2Footnote *
[17.4-37.0]
13.5Footnote
[10.9-16.1]
Any drug harm to self among those who have used/engaged in problematic use of any drugsFootnote 6 16.6
[13.8-19.4]
17.4
[13.4-21.4]
15.6
[11.6-19.5]
Footnote # 27.2Footnote *
[17.4-37.0]
13.5Footnote
[10.9-16.1]

[95% confidence intervals in brackets]

Footnote Note 1

At least one of 9 harms to: physical health; mental health; friendships and social life; financial position; home life or marriage; work, studies, or employment opportunities; legal problems; difficulty learning; housing problems.

Return to footnote 1 referrer

Footnote Note 2

Among those who have used any of 6 drugs (cocaine/crack, speed/methamphetamine, hallucinogens, salvia, ecstasy, heroin) in the past year. Drug related harms in the past year are due to any drug use. Users of any 6 drugs may also have used other drugs, including cannabis, or misused pharmaceuticals.

Return to footnote 2 referrer

Footnote Note 3

Cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom, other drugs). Drug related harms in the past year are due to any drug use. Users of any 11 drugs may also have used other drugs, including cannabis, or problematic use of pharmaceuticals.

Return to footnote 3 referrer

Footnote Note 4

Among those who have engaged in problematic use of pharmaceuticals (problematic use of pain killers [including low dose pain relievers], problematic use of stimulants, use of sedatives to get high) in the past year. Problematic users of pharmaceuticals may also have used illegal drugs and cannabis.

Return to footnote 4 referrer

Footnote Note 5

Among those who have used any drug (cannabis, cocaine/crack, speed/methamphetamine, hallucinogens, salvia, ecstasy, inhalants, heroin, abuse of pain killers [including low-dose pain relievers], abuse of stimulants, sedatives to get high) in the past year.

Return to footnote 5 referrer

Footnote Note 6

Among those who have used any drug (cannabis, cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, salvia, heroin, inhalants, synthetic cannabinoids, mephredone, kratom, BZP, other drugs, abuse of pain killers, abuse of stimulants, sedatives to get high) in the past year.

Return to footnote 6 referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ↑

Rounds up to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 18. Drug overdose, by sex and age group, 2019
N/A Overall Males Females 15-19 20-24 25+
Drug overdose - lifetimeFootnote 1 1.6
[1.1-2.1]
2.1
[1.2-3.0]
1.1
[0.7-1.6]
Footnote 3.9Footnote ^
[0.7-7.1]
1.2
[0.8-1.6]
Overdose interventionsFootnote 2
Call for an ambulance or bring you to the hospital 41.0Footnote *
[25.1-56.9]
Footnote # Footnote # Footnote - Footnote # Footnote #
Place you in rescue position 23.3Footnote *,Footnote ^
[8.4-38.2]
Footnote # Footnote # Footnote - Footnote Footnote #
Someone performed CPR or administered naloxone 20.3Footnote *,Footnote ^
[5.4-35.2]
Footnote Footnote # Footnote - Footnote Footnote #
Someone provided another kind of assistance 26.7Footnote *,Footnote ^
[12.0-41.5]
Footnote # Footnote # Footnote Footnote Footnote #
Any kind of intervention during overdoseFootnote 1 72.1Footnote *
[57.8-86.4]
Footnote # Footnote # Footnote Footnote # Footnote #
Naloxone
Obtained Naloxone kit - all respondents 1.8
[1.3-2.2]
1.7
[0.1-2.4]
1.8
[1.2-2.5]
Footnote 3.4Footnote ^
[0.5-6.3]
1.7
[1.2-2.2]
Obtained Naloxone kit - among opioid usersFootnote 3 3.5Footnote
[1.8-5.2]
2.6Footnote ^
[0.8-4.3]
4.2Footnote ^
[1.6-6.8]
Footnote Footnote 3.7
[1.8-5.5]
Reasons for obtaining a naloxone kit among those who received Naloxone kit
In case of need for oneself 12.2Footnote *,Footnote ^
[0.7-23.6]
Footnote Footnote Footnote - Footnote 9.4Footnote *,Footnote ^
[0.0-20.2]
In case of need for someone elseFootnote 4 68.8Footnote *
[55.9-81.7]
Footnote # Footnote # Footnote Footnote 71.0Footnote *
[58.0-84.0]
Other reason 19.0Footnote *,Footnote ^
[9.1-28.9]
Footnote # Footnote # Footnote - Footnote 19.6Footnote *,Footnote ^
[9.4-29.8]

[95% confidence intervals in brackets]

Footnote Note 1

Asked of those who used pain relievers, stimulants, sedatives, cannabis, cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, heroin, salvia, inhalants, synthetic cannabinoids, mephredone, kratom, BZP, other drugs, or over-the-counter medications.

Return to footnote 1 referrer

Footnote Note 2

Among those who reported experiencing an overdose involving pain relievers, stimulants, sedatives, cannabis, cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens heroin, salvia, inhalants, synthetic cannabinoids, mephedrone, kratom, other drugs, or over-the-counter medications.

Return to footnote 2 referrer

Footnote Note 3

Defined as users in the past 12 months of prescription opioid pain relievers (hydromorphone, Dilaudid, Hydromorph Contin, morphine, MS Contin, Demerol, oxycodone, fentanyl, codeine) or heroin.

Return to footnote 3 referrer

Footnote Note 4

Includes family, friend, or someone on the street or at a venue.

Return to footnote 4 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Footnote Note ↓

Rounds down to whole number.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 19. Drug overdose, by province, 2019
  Canada NL PE NS NB QC ON MB SK AB BC
Population estimate ('000) 30,995 440 130 813 635 7,089 12,253 1,044 893 3,558 4,140
Lifetime
Drug overdoseFootnote 1 1.6
[1.1-2.1]
Footnote 1.2Footnote ^
[0.2-2.1]
2.3Footnote ^
[0.6-4.0]
0.9Footnote ^
[0.1-1.8]
1.7Footnote ^
[0.6-2.8]
1.9Footnote ^
[0.9-3.0]
2.2Footnote ^
[0.9-3.5]
2.0Footnote ^
[0.4-3.5]
1.4Footnote ^
[0.1-2.6]
Footnote

[95% confidence intervals in brackets]

Footnote Note 1

Asked of those who used pain relievers, stimulants, sedatives, cannabis, cocaine/crack, amphetamines/methamphetamine, ecstasy, hallucinogens, heroin, salvia, inhalants, synthetic cannabinoids, mephredone, kratom, BZP, other drugs, or over-the-counter medications.

Return to footnote 1 referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 20. Received treatment for substance use, by sex and age group, 2019
N/A Overall Males Females 15-19 20-24 25+
Received treatmentFootnote 1 - lifetime 1.9
[1.5-2.4]
2.8
[2.1-3.5]
1.1
[0.7-1.5]
Footnote 3.8Footnote ^
[0.9-6.7]
1.9
[1.5-2.3]
Received treatmentFootnote 1 - past year 20.4Footnote ^
[11.4-29.4]
25.2Footnote *,Footnote ^
[13.5-37.0]
Footnote # Footnote Footnote 18.7Footnote ^
[10.0-27.5]
Received treatment for alcohol issue onlyFootnote 2 - past year Footnote # Footnote # Footnote Footnote Footnote Footnote #
Recieved treatment for drug issue onlyFootnote 2 - past year
Footnote # Footnote # Footnote Footnote - Footnote Footnote #

[95% confidence intervals in brackets]

Footnote Note 1

Received professional help (treatment or counselling given by doctors, counsellors, social workers or other health professionals) among those who reported using alcohol or drugs in their lifetime and receiving profesional help in their lifetime.

Return to footnote 1 referrer

Footnote Note 2

Among those who have ever received professional help for their alcohol or drug use.

Return to footnote 2 referrer

Footnote Note -

No observation.

Return to footnote - referrer

Footnote Note *

Estimates and confidence intervals are of marginal quality due to high sampling variability, and should be used with caution.

Return to * referrer

Footnote Note #

Estimates do not meet quality standards - conclusions based on these data will be unreliable, and may be invalid.

Return to # referrer

Footnote Note ^

Although 5 or more observations contribute to the numerator, the number of observations was below 30.

Return to ^ referrer

Footnote Note ‡

Although an estimate may be determined from the table, data should be suppressed to ensure confidentiality.

Return to referrer

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Table 21. Description of the sample, Canada, 2019
N/A Canada NL PE NS NB QC ON MB SK AB BC
Male 4,669 312 349 402 405 640 738 436 414 506 467
Female 5,624 432 478 489 498 792 900 518 491 477 549
15-19 272 19 23 14 16 26 51 35 31 32 25
20-24 319 14 23 32 20 49 57 41 25 27 31
25+ 9,702 711 781 845 867 1,357 1,530 878 849 924 960
25-34 1,196 73 82 86 85 161 194 129 125 141 120
35-44 1,619 114 97 126 125 242 246 152 157 198 162
45-54 1,518 127 127 131 138 219 252 123 126 137 138
55+ 5,369 397 475 502 519 735 838 474 441 448 540
Total 10,293 744 827 891 903 1,432 1,638 954 905 983 1,016

Source: Canadian Alcohol and Drugs Survey, June - December 2019.

Page details

Date modified: